Guodong Xu

10PUBLICATIONS
12CO-AUTHORS
PharmacogenomicsPredictive and prognostic markersImmunogenetics (incl. genetic immunology)Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|May 22, 2026
Exploratory research on drugs after lung surgery based on real-world data from the FDA adverse event reporting system database.

|Feb 27, 2026
Benign vs. malignant pulmonary nodules: pleural adhesion risks and predictors.

Jiaheng Zhang, Keyue Qiu, Hang Chen

|Mar 14, 2025
Survival advantage of radiotherapy and nomogram for patients with pulmonary neuroendocrine neoplasms: a propensity score-matched Surveillance, Epidemiology, and End Results database study.

Jingtao Tong, Kaitai Liu, Guodong Xu

|Nov 11, 2024
RBM15 facilitates osimertinib resistance of lung adenocarcinoma through m6A-dependent epigenetic silencing of SPOCK1.

Hongxiang Li, Yin Li, Xiaoxiao Zheng

|Sep 01, 2023
Lysosome-related genes: A new prognostic marker for lung adenocarcinoma.

Zeyang Hu, Hang Chen, Hongxiang Li

|Mar 17, 2023
IKZF3 is a novel prognostic biomarker for head and neck squamous cell carcinoma: A study based on bioinformatics analysis.

Hongxiang Li, Mengmeng Ye, Zeyang Hu

Pageof 2

Frequent Collaborators

2 joint publications

Kaitai Liu

1 joint publications

Hang Chen

1 joint publications

Chongchang Zhou

1 joint publications

Ling Wu